Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 11

NCT ID: NCT03214913 Not yet recruiting - Sepsis Clinical Trials

Controlled Fluid Resuscitation in Sepsis

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

To evaluate two different strategy of fluid resuscitation in sepsis patients

NCT ID: NCT02980588 Not yet recruiting - Sepsis Clinical Trials

The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis

Start date: December 2016
Phase: N/A
Study type: Interventional

Poorly glycemic control in critically ill patients can increase their mortality, while safe and efficient glucose control is laborious and time-consuming. The Space Glucose Control which is installed with eMPC(enhanced Model Predictive Control) can get the blood glucose target range safely and effectively through regulating insulin dose rate, and decrease the glucose variability. This study is a random controlled trial involving the patients with sepsis in intensive care unit in order to evaluate the difference of safety and efficacy of blood glucose control between SGC directed and conventional treatment. At last, the trial results can determine whether the Space Glucose Control can control blood glucose safely and effectively in the patients with sepsis in intensive care units.

NCT ID: NCT02910765 Not yet recruiting - Sepsis Clinical Trials

Methylene Blue and Ozone in Early Sepsis

Start date: October 2016
Phase: Phase 4
Study type: Interventional

effects of methylene blue and ozone O3 therapy effects in early sepsis management , and their implications upon outcome

NCT ID: NCT02768324 Not yet recruiting - Sepsis Clinical Trials

the Effect of Gut Microbiota on the Prognosis of Sepsis

Start date: May 1, 2017
Phase: N/A
Study type: Observational

Sepsis is a life-threatening condition that arises when the body's response to infection injures its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion. Clinically, sepsis patients with diarrhea often result in a bad prognosis. Gut microbiota consists of a complex community of microorganisms that live in the digestive tracts of animals. The gut microbiota comprises the largest and most diverse reservoir of mutualistic microorganisms associated with animals. The aims of this study is to determin the effect of gut microbiota on the prognosis of Sepsis, by using 16s pyrosequencing, comparing the blood culture result.

NCT ID: NCT02304224 Not yet recruiting - Sepsis Clinical Trials

the Relationship of the Use of Eye Masks and Outcomes of Patients With Sepsis in Intensive Care Unit

Start date: December 2014
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the relationship of nocturnal use of eye masks and immune function, cerebral function and outcomes of patients with sepsis. Thus more efficient and comprehensive treatment could be provided for patients in the duration of admission in intensive care unit.

NCT ID: NCT02195830 Not yet recruiting - Sepsis Clinical Trials

Inferior Vena Cava Collapsibility Index in Severe Sepsis

Start date: July 2014
Phase: N/A
Study type: Interventional

There is debate regarding the use of non invasive (ultrasound assessed) parameters of fluid volume status in patients with sepsis. To establish the role of inferior vena cava ultrasound in guiding fluid resuscitation we first need to define the inferior vena cava collapsibility index in this population of patients. The research question is: In adult patients with sepsis, severe sepsis and septic shock what is the mean baseline inferior vena cava collapsibility index (IVCCI) prior to fluid resuscitation.

NCT ID: NCT01992796 Not yet recruiting - Severe Sepsis Clinical Trials

Angiotensin II Antagonist in Severe Sepsis

SartSep
Start date: January 2014
Phase: Phase 3
Study type: Interventional

The investigators propose a clinical study of irbersartan for the early treatment of severe sepsis patients with elevated predicted risk of death between. This study will evaluate whether early administration of the the angiotensin receptor blocker irbersartan provides significant reduction of 28 days mortality and multi organ failure incidence to patients with severe sepsis.

NCT ID: NCT01858909 Not yet recruiting - Septic Shock Clinical Trials

Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock

Start date: May 2013
Phase: Phase 3
Study type: Interventional

OBJECTIVES. To establish the therapeutic efficiency of melatonin in adult patients with severe sepsis and septic shock. Specifically: 1. To evaluate the survival to 28 days of mechanical assisted ventilation, days with vasoactive drugs, need of hemodialysis-hemofiltration, superinfection and evolution towards the failure of other organs. 2. To evaluate, waiting for reduction under the influence of the treatment with melatonin, : 1. clinical - analytical parameters of sepsis; 2. levels of cytokines; 3. oxidative and nitrosative stress; 4. acute-phase proteins (APP), specially of the ITIH4; 5. immune response; 6. endocrine response. METHODOLOGY. Patients will be randomized in two groups, n = 55 in each group: 1) treatment with melatonin 30mg/12 hours 28 days; 2) placebo. Determinations: a) clinical - analytical parameters relative to the sepsis; b) melatonin plasmatic levels; c) quantification of malonyldialdehyde and 4-hydroxynonenal, protein carbonyl content, nitrites, erythrocyte membrane fluidity, and superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase activity; d) Interleukins-1,2,4,5, 6, 7,8,10,12,13, IFN-γ; TNF-α and GM-CSF; e) acute-phase proteins: PCR, haptoglobin, Apo A-I, α1-GPA and ITIH4; f) lymphocytes T, B, NK, T CD4, and T CD8, and immunoglobulins; g) cortisol, aldosterone, ACTH, ADH, insulin, glucagon and 25-hydroxyvitamin D3. Data will be analyzed following a prospectively define plan and by intention-to-treat (ITT) analysis.

NCT ID: NCT00628381 Not yet recruiting - Sepsis Clinical Trials

L-citrulline Supplementation During Sepsis

Start date: January 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study the stimulating effects of prolonged (8h) enteral L-citrulline supplementation on the normalisation of the plasma citrulline concentrations and the Arginine-NO metabolism, the microcirculation, the systemic hemodynamics, vascular permeability, and organ function and disease severity scores.